Understand the source comparison
Best Peptides for Internal Scar Tissue: Research Comparison
The table below compares the three peptides with the strongest preclinical evidence for influencing internal scar tissue, organized by mechanism, dosing range, and tissue-type suitability. BPC-157 VEGF upregulation, TGF-β downregulation, angiogenesis promotion
No winner is assigned.
This page preserves a source comparison for education. It does not add a rating, recommendation or clinical judgment.
- The table below compares the three peptides with the strongest preclinical evidence for influencing internal scar tissue, organized by mechanism, dosing range, and tissue-type suitability.
- BPC-157
- VEGF upregulation, TGF-β downregulation, angiogenesis promotion
- 10–100 mcg/kg SC/IP daily for 2–4 weeks
- Post-surgical adhesions, GI tract injury, tendon/ligament repair
- Strong preclinical (rodent models), limited human data
- Best evidence for adhesion prevention when dosed perioperatively; timing matters more than total dose
- TB-500
- Actin regulation, myofibroblast contractility reduction, cytoskeletal remodeling
- 2–10 mg SC twice weekly for 4–6 weeks
- Muscle fibrosis, traumatic soft tissue injury, joint capsule scarring
- Moderate preclinical (large animal models show effect)
- Most effective during proliferative phase (7–21 days post-injury); negligible benefit if started >4 weeks post-injury
- GHK-Cu
- MMP upregulation, collagen I/III ratio shift, decorin expression
- 1–3 mg SC/topical 3× weekly for 8–12 weeks
- Dermal scarring, organ capsule fibrosis, late-stage remodeling
- Emerging preclinical (strongest dermal data, limited visceral organ research)
- Long intervention window (effective 4+ weeks post-injury); requires extended dosing; copper oxidation during storage is primary failure point